@prefix rdf: . @prefix geo: . rdf:type geo:SpatialThing . @prefix dbo: . rdf:type dbo:Company . @prefix wikidata: . rdf:type wikidata:Q4830453 , wikidata:Q43229 , wikidata:Q24229398 . @prefix owl: . rdf:type owl:Thing . @prefix ns5: . rdf:type ns5:SocialPerson , ns5:Agent , dbo:Agent . @prefix schema: . rdf:type schema:Organization , dbo:Organisation . @prefix rdfs: . rdfs:label "Illumina"@pt , "Illumina"@de , "Illumina, Inc."@en , "\u56E0\u7F8E\u7EB3"@zh , "Illumina"@pl , "Illumina"@ru , "Illumina"@fr , "\u0625\u0644\u064A\u0648\u0645\u064A\u0646\u0627"@ar , "Illumina (empresa)"@ca , "Illumina (compa\u00F1\u00EDa)"@es , "Illumina (perusahaan)"@in ; rdfs:comment "Illumina Inc. \u00E9s una empresa nord-americana la seu de la qual s'allotja a San Diego, Calif\u00F2rnia. Fou fundada el 1998 i s'encarrega de desenvolupar, fabricar i comercialitzar sistemes integrats per a l'an\u00E0lisi de variacions gen\u00E8tiques i funcions biol\u00F2giques. Utilitzant les seves tecnologies, la companyia proporciona una l\u00EDnia de productes i serveis que distribueixen als mercats de sequenciaci\u00F3, genotipificaci\u00F3 i expressi\u00F3 gen\u00E8tica. Els clients inclouen centres de recerca gen\u00F2mica, empreses farmac\u00E8utiques, institucions acad\u00E8miques, organitzacions de recerca cl\u00EDnica i empreses biotecnol\u00F2giques. Les seves eines proporcionen als investigadors la capacitat per realitzar les proves gen\u00E8tiques pertinents per extreure informaci\u00F3 m\u00E8dica v\u00E0lida en aven\u00E7os de gen\u00F2mica i prote\u00F2mica."@ca , "Illumina, Inc. \u2013 ameryka\u0144skie przedsi\u0119biorstwo z siedzib\u0105 w San Diego, zajmuj\u0105ce si\u0119 produkcj\u0105 urz\u0105dze\u0144 i rozwi\u0105za\u0144 analizy genetycznej i genomicznej. Produkty firmy s\u0105 dystrybuowane w Ameryce P\u00F3\u0142nocnej, Ameryce \u0141aci\u0144skiej, Europie oraz w rejonie Azji i Pacyfiku. Illumina produkuje tak\u017Ce reagenty, kuwety przep\u0142ywowe i mikromacierze, kt\u00F3re w sumie w 2014 roku odpowiada\u0142y za 30% przychod\u00F3w firmy."@pl , "\u041A\u043E\u043C\u043F\u0430\u043D\u0438\u044F Illumina, Inc. (NASDAQ: ILMN), \u043E\u0441\u043D\u043E\u0432\u0430\u043D\u0430 \u0432 \u0430\u043F\u0440\u0435\u043B\u0435 1998 \u0433\u043E\u0434\u0430, \u0437\u0430\u043D\u0438\u043C\u0430\u0435\u0442\u0441\u044F \u0440\u0430\u0437\u0440\u0430\u0431\u043E\u0442\u043A\u043E\u0439, \u043F\u0440\u043E\u0438\u0437\u0432\u043E\u0434\u0441\u0442\u0432\u043E\u043C \u0438 \u0432\u043D\u0435\u0434\u0440\u0435\u043D\u0438\u0435\u043C \u0441\u0438\u0441\u0442\u0435\u043C \u0430\u043D\u0430\u043B\u0438\u0437\u0430 \u0433\u0435\u043D\u0435\u0442\u0438\u0447\u0435\u0441\u043A\u043E\u0433\u043E \u0440\u0430\u0437\u043D\u043E\u043E\u0431\u0440\u0430\u0437\u0438\u044F \u0438 \u0431\u0438\u043E\u043B\u043E\u0433\u0438\u0447\u0435\u0441\u043A\u0438\u0445 \u0444\u0443\u043D\u043A\u0446\u0438\u0439. Illumina \u043F\u0440\u043E\u0438\u0437\u0432\u043E\u0434\u0438\u0442 \u043B\u0438\u043D\u0435\u0439\u043A\u0443 \u043F\u0440\u043E\u0434\u0443\u043A\u0442\u043E\u0432 \u0438 \u0443\u0441\u043B\u0443\u0433 \u0434\u043B\u044F \u0441\u0435\u043A\u0432\u0435\u043D\u0438\u0440\u043E\u0432\u0430\u043D\u0438\u044F, \u0433\u0435\u043D\u043E\u0442\u0438\u043F\u0438\u0440\u043E\u0432\u0430\u043D\u0438\u044F \u0438 \u0438\u0437\u0443\u0447\u0435\u043D\u0438\u044F \u044D\u043A\u0441\u043F\u0440\u0435\u0441\u0441\u0438\u0438 \u0433\u0435\u043D\u043E\u0432. \u041A\u043B\u0438\u0435\u043D\u0442\u044B Illumina \u2014 \u0446\u0435\u043D\u0442\u0440\u044B \u0438\u0437\u0443\u0447\u0435\u043D\u0438\u044F \u0433\u0435\u043D\u043E\u043C\u043E\u0432, \u0444\u0430\u0440\u043C\u0430\u0446\u0435\u0432\u0442\u0438\u0447\u0435\u0441\u043A\u0438\u0435 \u043A\u043E\u043C\u043F\u0430\u043D\u0438\u0438, \u0443\u043D\u0438\u0432\u0435\u0440\u0441\u0438\u0442\u0435\u0442\u0441\u043A\u0438\u0435 \u0446\u0435\u043D\u0442\u0440\u044B, \u043E\u0440\u0433\u0430\u043D\u0438\u0437\u0430\u0446\u0438\u0438, \u043E\u0441\u0443\u0449\u0435\u0441\u0442\u0432\u043B\u044F\u044E\u0449\u0438\u0435 \u043A\u043B\u0438\u043D\u0438\u0447\u0435\u0441\u043A\u0438\u0435 \u0438\u0441\u0441\u043B\u0435\u0434\u043E\u0432\u0430\u043D\u0438\u044F, \u0430 \u0442\u0430\u043A\u0436\u0435 \u0431\u0438\u043E\u0442\u0435\u0445\u043D\u043E\u043B\u043E\u0433\u0438\u0447\u0435\u0441\u043A\u0438\u0435 \u043A\u043E\u043C\u043F\u0430\u043D\u0438\u0438. Illumina \u043F\u0440\u043E\u0438\u0437\u0432\u043E\u0434\u0438\u0442 \u0438\u043D\u0441\u0442\u0440\u0443\u043C\u0435\u043D\u0442\u044B, \u043A\u043E\u0442\u043E\u0440\u044B\u0435 \u043F\u043E\u0437\u0432\u043E\u043B\u044F\u044E\u0442 \u0438\u0441\u0441\u043B\u0435\u0434\u043E\u0432\u0430\u0442\u0435\u043B\u044F\u043C \u043E\u0441\u0443\u0449\u0435\u0441\u0442\u0432\u043B\u044F\u0442\u044C \u0433\u0435\u043D\u0435\u0442\u0438\u0447\u0435\u0441\u043A\u0438\u0435 \u0438\u0441\u0441\u043B\u0435\u0434\u043E\u0432\u0430\u043D\u0438\u044F, \u043D\u0435\u043E\u0431\u0445\u043E\u0434\u0438\u043C\u044B\u0435 \u0434\u043B\u044F \u043C\u0435\u0434\u0438\u0446\u0438\u043D\u044B, \u0433\u0435\u043D\u043E\u043C\u0438\u043A\u0438 \u0438 \u043F\u0440\u043E\u0442\u0435\u043E\u043C\u0438\u043A\u0438."@ru , "Illumina ist ein US-amerikanischer Hersteller von Ger\u00E4ten f\u00FCr die Gentechnik mit Sitz in San Diego. Das Unternehmen wurde 1998 gegr\u00FCndet und ging im Jahr 2000 an die B\u00F6rse. Von 1999 bis Ende 2016 wurde Illumina von Jay Flatley geleitet. 2007 \u00FCbernahm Illumina die Firma Solexa. Bei Solexa wurde die Solexa/Illumina DNA-Sequenzierungsmethode entwickelt (von David Klenerman und Shankar Balasubramanian, die 1998 Solexa gr\u00FCndeten). 2006 \u00FCbernahm Illumina Solexa f\u00FCr 600 Millionen Dollar. 2022 verbot die EU-Kommission die Fusion von Illumina mit . \n* Sequenzierger\u00E4t MiSeq \n* S.-ger\u00E4t HiSeq 2500"@de , "Illumina, Inc. is an American biotechnology company, headquartered in San Diego, California. Incorporated on April 1, 1998, Illumina develops, manufactures, and markets integrated systems for the analysis of genetic variation and biological function. The company provides a line of products and services that serves the sequencing, genotyping and gene expression, and proteomics markets."@en , "\u56E0\u7F8E\u7EB3\uFF08\u82F1\u8A9E\uFF1AIllumina\uFF09\u662F\u7F8E\u56FD\u7684\u4E00\u5BB6\u751F\u7269\u79D1\u6280\u516C\u53F8\uFF0C\u6210\u7ACB\u4E8E1998\u5E74\uFF0C\u603B\u90E8\u8BBE\u4E8E\u52A0\u5229\u798F\u5C3C\u4E9A\u5DDE\u5723\u5730\u4E9A\u54E5\u3002\u5B83\u5728\u5DF4\u897F\u3001\u82F1\u56FD\u3001\u8377\u5170\u3001\u4E2D\u56FD\u3001\u65B0\u52A0\u5761\u3001\u65E5\u672C\u3001\u6FB3\u5927\u5229\u4E9A\u4E5F\u8BBE\u6709\u5206\u90E8\u3002\u5176\u5458\u5DE5\u8D85\u8FC73000\u4EBA\uFF0C2013\u5E74\u603B\u6536\u5165\u8FBE14.2\u4EBF\u3002\u8BE5\u516C\u53F8\u4E13\u6CE8\u4E8E\u751F\u7269\u4FE1\u606F\u5206\u6790\uFF0C\u63D0\u4F9B\u6709\u5173SNP\u57FA\u56E0\u5206\u578B\u3001\uFF08CNV\uFF09\u3001\u57FA\u56E0\u7EC4\u6D4B\u5E8F\u3001DNA\u7532\u57FA\u5316\u7814\u7A76\u3001\u3001\u76F8\u5173\u7684\u670D\u52A1\u3002\u5982\u4ECA\u7684Illumina\u5DF2\u7ECF\u5360\u6709\u4E86\u57FA\u56E0\u7EC4\u6D4B\u5E8F\u9886\u57DF70%\u7684\u5E02\u573A\u4EFD\u989D\uFF0C\u57282014\u5E74\u8FD8\u88AB\u300AMIT\u6280\u672F\u8BC4\u8BBA\u300B\u9009\u4E3A\u5E74\u5EA650\u5BB6\u6700\u806A\u660E\u516C\u53F8\u7B2C\u4E00\u4F4D\u3002"@zh , "Illumina Inc. (NASDAQ: ILMN) \u00E9 uma empresa americana l\u00EDder no segmento de decodifica\u00E7\u00E3o de informa\u00E7\u00E3o gen\u00E9tica, localizada em San Diego, Calif\u00F3rnia. A empresa fabrica e comercializa sistemas integrados para an\u00E1lise de varia\u00E7\u00E3o gen\u00E9tica e fun\u00E7\u00E3o biol\u00F3gica. Sua linha de produtos e de servi\u00E7o \u00E9 composta por sequenciadores de DNA bem como seus acess\u00F3rios que podem ser aplicados em estudos sobre c\u00E2ncer, doen\u00E7as contagiosas, processos de reprodu\u00E7\u00E3o assistida, etc."@pt , "Illumina, Inc. est une soci\u00E9t\u00E9 am\u00E9ricaine constitu\u00E9e en avril 1998, qui d\u00E9veloppe, fabrique et commercialise des syst\u00E8mes int\u00E9gr\u00E9s pour l'analyse de la variation g\u00E9n\u00E9tique et la fonction biologique. Gr\u00E2ce \u00E0 ses technologies, la soci\u00E9t\u00E9 fournit une gamme de produits et services qui servent les march\u00E9s du s\u00E9quen\u00E7age, g\u00E9notypage et expression g\u00E9n\u00E9tique. En 2013, cette technologie avait r\u00E9duit le co\u00FBt de s\u00E9quen\u00E7age de l'ADN \u00E0 4 000 dollars, compar\u00E9 \u00E0 1 million de dollars en 2007."@fr , "Illumina, Inc. es una compa\u00F1\u00EDa estadounidense fundada en abril de 1998 que desarrolla, fabrica y comercializa sistemas integrados para el an\u00E1lisis de variaci\u00F3n gen\u00E9tica y funci\u00F3n biol\u00F3gica. En 2014 fue nombrada por MIT Technology Review como \"la compa\u00F1\u00EDa m\u00E1s inteligente del mundo\". Mediante el uso de su tecnolog\u00EDa, Illumina proporciona una l\u00EDnea de productos y servicios que sirven a los mercados de secuenciaci\u00F3n, genotipado y expresi\u00F3n g\u00E9nica. Esta tecnolog\u00EDa ha conseguido reducir el coste de secuenciar el genoma humano desde $1.000.000 en 2007 a $4 000 en 2013. Sus clientes incluyen centros de investigaci\u00F3n gen\u00F3mica, compa\u00F1\u00EDas farmac\u00E9uticas, instituciones acad\u00E9micas, organizaciones de investigaci\u00F3n cl\u00EDnica y compa\u00F1\u00EDas biotecnol\u00F3gicas. Sus herramientas proporcionan a los investigadores la "@es , "\u0634\u0631\u0643\u0629 \u0625\u0644\u064A\u0648\u0645\u064A\u0646\u0627 (\u0628\u0627\u0644\u0625\u0646\u062C\u0644\u064A\u0632\u064A\u0629: Illumina, Inc.)\u200F \u0647\u064A \u0634\u0631\u0643\u0629 \u0623\u0645\u0631\u064A\u0643\u064A\u0629 \u0645\u0642\u0631\u0647\u0627 \u0641\u064A \u0633\u0627\u0646 \u062F\u064A\u064A\u063A\u0648\u060C \u0643\u0627\u0644\u064A\u0641\u0648\u0631\u0646\u064A\u0627\u060C \u062A\u0623\u0633\u0633\u062A \u0641\u064A \u0639\u0627\u0645 1998. \u062A\u0642\u0648\u0645 \u0627\u0644\u0634\u0631\u0643\u0629 \u0628\u062A\u0637\u0648\u064A\u0631 \u0648\u062A\u0635\u0646\u064A\u0639 \u0648\u062A\u0633\u0648\u064A\u0642 \u0627\u0644\u0623\u0646\u0638\u0645\u0629 \u0627\u0644\u0645\u062A\u0643\u0627\u0645\u0644\u0629 \u0644\u062A\u062D\u0644\u064A\u0644 \u0627\u0644\u0627\u062E\u062A\u0644\u0627\u0641 \u0627\u0644\u0648\u0631\u0627\u062B\u064A \u0648\u0627\u0644\u0648\u0638\u064A\u0641\u0629 \u0627\u0644\u062D\u064A\u0648\u064A\u0629. \u0627\u062E\u062A\u064A\u0631\u062A \u0627\u0644\u0634\u0631\u0643\u0629 \u0641\u064A \u0639\u0627\u0645 2014 \u0639\u0644\u0649 \u0623\u0646\u0647\u0627 \u0623\u0630\u0643\u0649 \u0634\u0631\u0643\u0629 \u0641\u064A \u0627\u0644\u0639\u0627\u0644\u0645 \u0628\u062D\u0633\u0628 \u0645\u062C\u0644\u0629 \u0625\u0645 \u0622\u064A \u062A\u064A \u062A\u0643\u0646\u0648\u0644\u0648\u062C\u064A \u0631\u064A\u0641\u064A\u0648 \u0627\u0644\u0635\u0627\u062F\u0631\u0629 \u0639\u0646 \u0645\u0639\u0647\u062F \u0645\u0627\u0633\u0627\u062A\u0634\u0648\u0633\u062A\u0633 \u0644\u0644\u062A\u0643\u0646\u0648\u0644\u0648\u062C\u064A\u0627. \u062A\u0633\u062A\u0639\u0645\u0644 \u0627\u0644\u0634\u0631\u0643\u0629 \u062A\u0642\u0646\u064A\u0627\u062A \u062A\u0648\u0641\u0631 \u062E\u0637\u0648\u0637\u0627 \u0625\u0646\u062A\u0627\u062C\u064A\u0629 \u0641\u064A \u0645\u062C\u0627\u0644\u0627\u062A \u0648\u0627\u0644\u062A\u0639\u0628\u064A\u0631 \u0627\u0644\u062C\u064A\u0646\u064A. \u062E\u0641\u0636\u062A \u062A\u0642\u0646\u064A\u0627\u062A \u0627\u0644\u0634\u0631\u0643\u0629 \u062A\u0643\u0627\u0644\u064A\u0641 \u062A\u0633\u0644\u0633\u0644 \u0627\u0644\u062C\u064A\u0646\u0648\u0645 \u0627\u0644\u0628\u0634\u0631\u064A \u0645\u0646 \u0645\u0644\u064A\u0648\u0646 \u062F\u0648\u0644\u0627\u0631 \u0641\u064A \u0639\u0627\u0645 2007 \u0625\u0644\u0649 4000 \u062F\u0648\u0644\u0627\u0631 \u0641\u064A \u0639\u0627\u0645 2013."@ar , "Illumina.Inc merupakan perusahaan yang berada di Amerika yang didirikan pada bulan April 1988 yang mengembangkan, serta memasarkan analisis variasi genetika dan biologi fungsional. Teknologi yang diciptakannya menyediakan jasa genomik modern, seperti sekuensing, genotiping, dan ekspresi genetika. Pelanggan yang menggunakan jasanya umumnya berasal dari akademisi, lembaga riset, perusahaan bioteknologi."@in . @prefix foaf: . foaf:name "Illumina, Inc."@en ; foaf:homepage . @prefix dbp: . dbp:name "Illumina"@en , "Illumina, Inc."@en . @prefix xsd: . geo:lat "32.887592"^^xsd:float ; geo:long "-117.17306"^^xsd:float ; foaf:depiction , , , , ; dbp:secCik 1110803 . @prefix dcterms: . @prefix dbc: . dcterms:subject dbc:DNA_sequencing , dbc:American_companies_established_in_1998 , dbc:Health_care_companies_based_in_California , , dbc:Biotechnology_companies_of_the_United_States , dbc:Genomics_companies , dbc:Microarrays , dbc:Companies_based_in_San_Diego , , dbc:Biotechnology_companies_established_in_1998 ; dbo:wikiPageID 9003300 ; dbo:wikiPageRevisionID 1121362361 . @prefix dbr: . dbo:wikiPageWikiLink dbr:Anthony_Czarnik , dbr:Vertical_merger , dbr:Cornell_University , dbr:Pacific_Biosciences , , dbc:DNA_sequencing , dbr:Wisconsin , dbr:United_States_Court_of_Appeals_for_the_Federal_Circuit , dbr:California_Unfair_Competition_Law , dbc:American_companies_established_in_1998 , , dbr:Mammography , dbc:Biotechnology_companies_of_the_United_States , dbr:Sanger_sequencing , dbr:Manteia_Predictive_Medicine , , dbr:Francis_deSouza , , dbr:Larry_Bock , dbr:Bill_Gates , dbr:Public_company , dbc:Health_care_companies_based_in_California , dbr:Personal_genomics , dbr:Shankar_Balasubramanian , dbr:BGI_Group , dbr:Biotechnology , dbr:Full_Genome_Sequencing , dbc:Genomics_companies , dbr:Proteomics , dbr:Tufts_University , , dbc:Microarrays , dbr:Tumor_marker , dbr:San_Diego , , , dbr:Complete_Genomics , dbr:Data_compression_algorithm , dbr:Protein_analysis , dbr:Corporate_spin-off , dbr:NASDAQ-100 , dbr:Single_nucleotide_polymorphism , dbr:DNTP , dbr:Federal_antitrust_prosecution , , dbr:Oxford_Nanopore_Technologies , , dbr:David_Klenerman , dbr:Mycobacterium_smegmatis , dbc:Companies_based_in_San_Diego , dbr:Minnesota , dbr:Helmy_Eltoukhy , , dbr:Jeff_Bezos , dbr:Supreme_Court_of_the_United_States , , dbr:Human_genome , dbr:Hoffmann-La_Roche , dbr:Series_A_round , dbr:United_States , dbr:Mayo_Clinic , dbr:Sequencing , dbr:Nucleic_acid_thermodynamics , dbr:Genotyping , , , , dbr:DNA_sequencing , dbr:Patent_infringement , dbr:Guardant_Health , dbr:Federal_Trade_Commission , dbr:Gene_expression , dbc:Biotechnology_companies_established_in_1998 , dbr:DNA_polymerase , , dbr:Blood_test , dbr:Chief_Scientific_Officer ; dbo:wikiPageExternalLink , . @prefix dbpedia-et: . owl:sameAs dbpedia-et:Illumina . @prefix dbpedia-pl: . owl:sameAs dbpedia-pl:Illumina . @prefix dbpedia-pt: . owl:sameAs dbpedia-pt:Illumina . @prefix dbpedia-de: . owl:sameAs dbpedia-de:Illumina . @prefix dbpedia-fr: . owl:sameAs dbpedia-fr:Illumina , , , , . @prefix dbpedia-ms: . owl:sameAs dbpedia-ms:Illumina , , , , wikidata:Q2068984 , . @prefix ns20: . owl:sameAs ns20:xQpN . @prefix dbpedia-ru: . owl:sameAs dbpedia-ru:Illumina . @prefix dbt: . dbp:wikiPageUsesTemplate dbt:Commons_category , dbt:Authority_control , dbt:USD , dbt:Reflist , dbt:Tree_list . @prefix ns23: . dbp:wikiPageUsesTemplate ns23:end , dbt:Coord , dbt:Infobox_company , dbt:Self-published_inline , dbt:Finance_links , dbt:Short_description , dbt:Main_article , dbt:Ubl , dbt:Official , dbt:NASDAQ-100 , dbt:Start_date_and_age , dbt:As_of , dbt:Decrease , dbt:Increase ; dbo:thumbnail ; dbp:google "ILMN"@en ; dbp:yahoo "ILMN"@en . @prefix dbd: . dbp:assets "1.521E10"^^dbd:usDollar ; dbp:certain "yes"@en ; dbp:date "July 2016"@en ; dbp:equity "1.074E10"^^dbd:usDollar ; dbp:founders "David Walt"@en , "Mark Chee"@en , ""@en , dbr:Anthony_Czarnik , "John Stuelpnagel"@en , dbr:Larry_Bock ; dbp:homepage ; dbp:industry dbr:Biotechnology ; dbp:keyPeople dbr:Francis_deSouza , , ""@en ; dbp:locationCity ; dbp:locationCountry dbr:United_States ; dbp:logo "Illumina logo.svg"@en ; dbp:netIncome "7.6E8"^^dbd:usDollar ; dbp:numEmployees 9100 ; dbp:operatingIncome "US$−0.12 billion"@en ; dbp:products "NovaSeq 6000"@en , "HiSeq 4000"@en , "NextSeq 550Dx"@en , "NextSeq1000"@en , "MiSeq"@en , "iSeq 100"@en , "HiSeq X"@en , "NextSeq2000"@en , "MiSeqDx"@en , ""@en , "NextSeq 550"@en , "iScan"@en , "MiniSeq"@en ; dbp:revenue ""@en , "4.53E9"^^dbd:usDollar ; dbp:symbol "ILMN"@en ; dbp:type dbr:Public_company . @prefix georss: . georss:point "32.8875924 -117.1730577" ; dbo:abstract "Illumina.Inc merupakan perusahaan yang berada di Amerika yang didirikan pada bulan April 1988 yang mengembangkan, serta memasarkan analisis variasi genetika dan biologi fungsional. Teknologi yang diciptakannya menyediakan jasa genomik modern, seperti sekuensing, genotiping, dan ekspresi genetika. Pelanggan yang menggunakan jasanya umumnya berasal dari akademisi, lembaga riset, perusahaan bioteknologi."@in , "Illumina ist ein US-amerikanischer Hersteller von Ger\u00E4ten f\u00FCr die Gentechnik mit Sitz in San Diego. Das Unternehmen wurde 1998 gegr\u00FCndet und ging im Jahr 2000 an die B\u00F6rse. Von 1999 bis Ende 2016 wurde Illumina von Jay Flatley geleitet. 2007 \u00FCbernahm Illumina die Firma Solexa. Bei Solexa wurde die Solexa/Illumina DNA-Sequenzierungsmethode entwickelt (von David Klenerman und Shankar Balasubramanian, die 1998 Solexa gr\u00FCndeten). 2006 \u00FCbernahm Illumina Solexa f\u00FCr 600 Millionen Dollar. 2022 verbot die EU-Kommission die Fusion von Illumina mit . Illumina besitzt einen Marktanteil von 71 % bei Sequenzierautomaten. Die Sequenzierer detektieren, wie die Sanger-Sequenzierung, mittels sequencing-by-synthesis (SBS). \n* Sequenzierger\u00E4t MiSeq \n* S.-ger\u00E4t HiSeq 2500"@de , "\u041A\u043E\u043C\u043F\u0430\u043D\u0438\u044F Illumina, Inc. (NASDAQ: ILMN), \u043E\u0441\u043D\u043E\u0432\u0430\u043D\u0430 \u0432 \u0430\u043F\u0440\u0435\u043B\u0435 1998 \u0433\u043E\u0434\u0430, \u0437\u0430\u043D\u0438\u043C\u0430\u0435\u0442\u0441\u044F \u0440\u0430\u0437\u0440\u0430\u0431\u043E\u0442\u043A\u043E\u0439, \u043F\u0440\u043E\u0438\u0437\u0432\u043E\u0434\u0441\u0442\u0432\u043E\u043C \u0438 \u0432\u043D\u0435\u0434\u0440\u0435\u043D\u0438\u0435\u043C \u0441\u0438\u0441\u0442\u0435\u043C \u0430\u043D\u0430\u043B\u0438\u0437\u0430 \u0433\u0435\u043D\u0435\u0442\u0438\u0447\u0435\u0441\u043A\u043E\u0433\u043E \u0440\u0430\u0437\u043D\u043E\u043E\u0431\u0440\u0430\u0437\u0438\u044F \u0438 \u0431\u0438\u043E\u043B\u043E\u0433\u0438\u0447\u0435\u0441\u043A\u0438\u0445 \u0444\u0443\u043D\u043A\u0446\u0438\u0439. Illumina \u043F\u0440\u043E\u0438\u0437\u0432\u043E\u0434\u0438\u0442 \u043B\u0438\u043D\u0435\u0439\u043A\u0443 \u043F\u0440\u043E\u0434\u0443\u043A\u0442\u043E\u0432 \u0438 \u0443\u0441\u043B\u0443\u0433 \u0434\u043B\u044F \u0441\u0435\u043A\u0432\u0435\u043D\u0438\u0440\u043E\u0432\u0430\u043D\u0438\u044F, \u0433\u0435\u043D\u043E\u0442\u0438\u043F\u0438\u0440\u043E\u0432\u0430\u043D\u0438\u044F \u0438 \u0438\u0437\u0443\u0447\u0435\u043D\u0438\u044F \u044D\u043A\u0441\u043F\u0440\u0435\u0441\u0441\u0438\u0438 \u0433\u0435\u043D\u043E\u0432. \u041A\u043B\u0438\u0435\u043D\u0442\u044B Illumina \u2014 \u0446\u0435\u043D\u0442\u0440\u044B \u0438\u0437\u0443\u0447\u0435\u043D\u0438\u044F \u0433\u0435\u043D\u043E\u043C\u043E\u0432, \u0444\u0430\u0440\u043C\u0430\u0446\u0435\u0432\u0442\u0438\u0447\u0435\u0441\u043A\u0438\u0435 \u043A\u043E\u043C\u043F\u0430\u043D\u0438\u0438, \u0443\u043D\u0438\u0432\u0435\u0440\u0441\u0438\u0442\u0435\u0442\u0441\u043A\u0438\u0435 \u0446\u0435\u043D\u0442\u0440\u044B, \u043E\u0440\u0433\u0430\u043D\u0438\u0437\u0430\u0446\u0438\u0438, \u043E\u0441\u0443\u0449\u0435\u0441\u0442\u0432\u043B\u044F\u044E\u0449\u0438\u0435 \u043A\u043B\u0438\u043D\u0438\u0447\u0435\u0441\u043A\u0438\u0435 \u0438\u0441\u0441\u043B\u0435\u0434\u043E\u0432\u0430\u043D\u0438\u044F, \u0430 \u0442\u0430\u043A\u0436\u0435 \u0431\u0438\u043E\u0442\u0435\u0445\u043D\u043E\u043B\u043E\u0433\u0438\u0447\u0435\u0441\u043A\u0438\u0435 \u043A\u043E\u043C\u043F\u0430\u043D\u0438\u0438. Illumina \u043F\u0440\u043E\u0438\u0437\u0432\u043E\u0434\u0438\u0442 \u0438\u043D\u0441\u0442\u0440\u0443\u043C\u0435\u043D\u0442\u044B, \u043A\u043E\u0442\u043E\u0440\u044B\u0435 \u043F\u043E\u0437\u0432\u043E\u043B\u044F\u044E\u0442 \u0438\u0441\u0441\u043B\u0435\u0434\u043E\u0432\u0430\u0442\u0435\u043B\u044F\u043C \u043E\u0441\u0443\u0449\u0435\u0441\u0442\u0432\u043B\u044F\u0442\u044C \u0433\u0435\u043D\u0435\u0442\u0438\u0447\u0435\u0441\u043A\u0438\u0435 \u0438\u0441\u0441\u043B\u0435\u0434\u043E\u0432\u0430\u043D\u0438\u044F, \u043D\u0435\u043E\u0431\u0445\u043E\u0434\u0438\u043C\u044B\u0435 \u0434\u043B\u044F \u043C\u0435\u0434\u0438\u0446\u0438\u043D\u044B, \u0433\u0435\u043D\u043E\u043C\u0438\u043A\u0438 \u0438 \u043F\u0440\u043E\u0442\u0435\u043E\u043C\u0438\u043A\u0438."@ru , "Illumina, Inc. \u2013 ameryka\u0144skie przedsi\u0119biorstwo z siedzib\u0105 w San Diego, zajmuj\u0105ce si\u0119 produkcj\u0105 urz\u0105dze\u0144 i rozwi\u0105za\u0144 analizy genetycznej i genomicznej. Produkty firmy s\u0105 dystrybuowane w Ameryce P\u00F3\u0142nocnej, Ameryce \u0141aci\u0144skiej, Europie oraz w rejonie Azji i Pacyfiku. Firma dostarcza swoje urz\u0105dzenia analityczne do genomicznych centr\u00F3w badawczych, instytucji naukowych, laboratori\u00F3w rz\u0105dowych, szpitali i laboratori\u00F3w referencyjnych, a tak\u017Ce do przedsi\u0119biorstw farmaceutycznych, biotechnologicznych, agrogenomicznych oraz przedsi\u0119biorstw analizy molekularnej i genomicznej. Maszyn i rozwi\u0105za\u0144 Illumina u\u017Cyto do opracowania ponad 10 tys. prac naukowych. Illumina produkuje tak\u017Ce reagenty, kuwety przep\u0142ywowe i mikromacierze, kt\u00F3re w sumie w 2014 roku odpowiada\u0142y za 30% przychod\u00F3w firmy. G\u0142\u00F3wne centrum badawczo-rozwojowe, a tak\u017Ce dystrybucyjne, magazynowe i administracyjne firmy znajduje si\u0119 w San Diego. Pozosta\u0142e centra znajduj\u0105 si\u0119 w Madison, San Francisco, Cambridge, Eindhoven oraz w Singapurze."@pl , "Illumina Inc. \u00E9s una empresa nord-americana la seu de la qual s'allotja a San Diego, Calif\u00F2rnia. Fou fundada el 1998 i s'encarrega de desenvolupar, fabricar i comercialitzar sistemes integrats per a l'an\u00E0lisi de variacions gen\u00E8tiques i funcions biol\u00F2giques. Utilitzant les seves tecnologies, la companyia proporciona una l\u00EDnia de productes i serveis que distribueixen als mercats de sequenciaci\u00F3, genotipificaci\u00F3 i expressi\u00F3 gen\u00E8tica. Els clients inclouen centres de recerca gen\u00F2mica, empreses farmac\u00E8utiques, institucions acad\u00E8miques, organitzacions de recerca cl\u00EDnica i empreses biotecnol\u00F2giques. Les seves eines proporcionen als investigadors la capacitat per realitzar les proves gen\u00E8tiques pertinents per extreure informaci\u00F3 m\u00E8dica v\u00E0lida en aven\u00E7os de gen\u00F2mica i prote\u00F2mica."@ca , "Illumina Inc. (NASDAQ: ILMN) \u00E9 uma empresa americana l\u00EDder no segmento de decodifica\u00E7\u00E3o de informa\u00E7\u00E3o gen\u00E9tica, localizada em San Diego, Calif\u00F3rnia. A empresa fabrica e comercializa sistemas integrados para an\u00E1lise de varia\u00E7\u00E3o gen\u00E9tica e fun\u00E7\u00E3o biol\u00F3gica. Sua linha de produtos e de servi\u00E7o \u00E9 composta por sequenciadores de DNA bem como seus acess\u00F3rios que podem ser aplicados em estudos sobre c\u00E2ncer, doen\u00E7as contagiosas, processos de reprodu\u00E7\u00E3o assistida, etc. A Illumina chama aten\u00E7\u00E3o pela sua efici\u00EAncia em baixar o custo dos estudos de genomas humanos. Um processo que em 2007 custava cerca de 1 milh\u00E3o de d\u00F3lares, atualmente pode ser realizado com os equipamentos da empresa por cerca de mil d\u00F3lares e com proje\u00E7\u00E3o de cair para 100 d\u00F3lares em poucos anos."@pt , "\u0634\u0631\u0643\u0629 \u0625\u0644\u064A\u0648\u0645\u064A\u0646\u0627 (\u0628\u0627\u0644\u0625\u0646\u062C\u0644\u064A\u0632\u064A\u0629: Illumina, Inc.)\u200F \u0647\u064A \u0634\u0631\u0643\u0629 \u0623\u0645\u0631\u064A\u0643\u064A\u0629 \u0645\u0642\u0631\u0647\u0627 \u0641\u064A \u0633\u0627\u0646 \u062F\u064A\u064A\u063A\u0648\u060C \u0643\u0627\u0644\u064A\u0641\u0648\u0631\u0646\u064A\u0627\u060C \u062A\u0623\u0633\u0633\u062A \u0641\u064A \u0639\u0627\u0645 1998. \u062A\u0642\u0648\u0645 \u0627\u0644\u0634\u0631\u0643\u0629 \u0628\u062A\u0637\u0648\u064A\u0631 \u0648\u062A\u0635\u0646\u064A\u0639 \u0648\u062A\u0633\u0648\u064A\u0642 \u0627\u0644\u0623\u0646\u0638\u0645\u0629 \u0627\u0644\u0645\u062A\u0643\u0627\u0645\u0644\u0629 \u0644\u062A\u062D\u0644\u064A\u0644 \u0627\u0644\u0627\u062E\u062A\u0644\u0627\u0641 \u0627\u0644\u0648\u0631\u0627\u062B\u064A \u0648\u0627\u0644\u0648\u0638\u064A\u0641\u0629 \u0627\u0644\u062D\u064A\u0648\u064A\u0629. \u0627\u062E\u062A\u064A\u0631\u062A \u0627\u0644\u0634\u0631\u0643\u0629 \u0641\u064A \u0639\u0627\u0645 2014 \u0639\u0644\u0649 \u0623\u0646\u0647\u0627 \u0623\u0630\u0643\u0649 \u0634\u0631\u0643\u0629 \u0641\u064A \u0627\u0644\u0639\u0627\u0644\u0645 \u0628\u062D\u0633\u0628 \u0645\u062C\u0644\u0629 \u0625\u0645 \u0622\u064A \u062A\u064A \u062A\u0643\u0646\u0648\u0644\u0648\u062C\u064A \u0631\u064A\u0641\u064A\u0648 \u0627\u0644\u0635\u0627\u062F\u0631\u0629 \u0639\u0646 \u0645\u0639\u0647\u062F \u0645\u0627\u0633\u0627\u062A\u0634\u0648\u0633\u062A\u0633 \u0644\u0644\u062A\u0643\u0646\u0648\u0644\u0648\u062C\u064A\u0627. \u062A\u0633\u062A\u0639\u0645\u0644 \u0627\u0644\u0634\u0631\u0643\u0629 \u062A\u0642\u0646\u064A\u0627\u062A \u062A\u0648\u0641\u0631 \u062E\u0637\u0648\u0637\u0627 \u0625\u0646\u062A\u0627\u062C\u064A\u0629 \u0641\u064A \u0645\u062C\u0627\u0644\u0627\u062A \u0648\u0627\u0644\u062A\u0639\u0628\u064A\u0631 \u0627\u0644\u062C\u064A\u0646\u064A. \u062E\u0641\u0636\u062A \u062A\u0642\u0646\u064A\u0627\u062A \u0627\u0644\u0634\u0631\u0643\u0629 \u062A\u0643\u0627\u0644\u064A\u0641 \u062A\u0633\u0644\u0633\u0644 \u0627\u0644\u062C\u064A\u0646\u0648\u0645 \u0627\u0644\u0628\u0634\u0631\u064A \u0645\u0646 \u0645\u0644\u064A\u0648\u0646 \u062F\u0648\u0644\u0627\u0631 \u0641\u064A \u0639\u0627\u0645 2007 \u0625\u0644\u0649 4000 \u062F\u0648\u0644\u0627\u0631 \u0641\u064A \u0639\u0627\u0645 2013. \u062A\u0634\u0645\u0644 \u0642\u0627\u0626\u0645\u0629 \u0632\u0628\u0627\u0626\u0646 \u0627\u0644\u0634\u0631\u0643\u0629 \u0645\u0631\u0627\u0643\u0632 \u0623\u0628\u062D\u0627\u062B \u0627\u0644\u062C\u064A\u0646\u0648\u0645 \u0648\u0634\u0631\u0643\u0629 \u0635\u064A\u062F\u0644\u0627\u0646\u064A\u0629 \u0648\u0645\u0624\u0633\u0633\u0627\u062A \u0623\u0643\u0627\u062F\u064A\u0645\u064A\u0629 \u0648\u0645\u0646\u0638\u0645\u0627\u062A \u0623\u0628\u062D\u0627\u062B \u0633\u0631\u064A\u0631\u064A\u0629 \u0648\u0634\u0631\u0643\u0627\u062A \u062A\u0642\u0627\u0646\u0629 \u062D\u064A\u0648\u064A\u0629\u060C \u0648\u062A\u0648\u0641\u0631 \u0623\u062F\u0648\u0627\u062A \u0627\u0644\u0634\u0631\u0643\u0629 \u0627\u0644\u0642\u062F\u0631\u0629 \u0644\u0644\u0628\u0627\u062D\u062B\u064A\u0646 \u0644\u0623\u062C\u0644 \u0627\u062F\u0627\u0621 \u0627\u0644\u0627\u062E\u062A\u0628\u0627\u0631\u0627\u062A \u0627\u0644\u062C\u064A\u0646\u064A\u0629 \u0627\u0644\u0636\u0631\u0648\u0631\u064A\u0629 \u0644\u0627\u0633\u062A\u062E\u0644\u0627\u0635 \u0627\u0644\u0645\u0639\u0644\u0648\u0645\u0627\u062A \u0627\u0644\u0637\u0628\u064A\u0629 \u0645\u0646 \u0645\u0639\u0644\u0648\u0645\u0627\u062A \u0645\u0642\u062F\u0645\u0629 \u0645\u0646 \u0627\u0644\u062C\u064A\u0646\u0648\u0645 \u0648\u0627\u0644\u0628\u0631\u0648\u062A\u064A\u0648\u0645\u064A\u0627\u062A."@ar , "\u56E0\u7F8E\u7EB3\uFF08\u82F1\u8A9E\uFF1AIllumina\uFF09\u662F\u7F8E\u56FD\u7684\u4E00\u5BB6\u751F\u7269\u79D1\u6280\u516C\u53F8\uFF0C\u6210\u7ACB\u4E8E1998\u5E74\uFF0C\u603B\u90E8\u8BBE\u4E8E\u52A0\u5229\u798F\u5C3C\u4E9A\u5DDE\u5723\u5730\u4E9A\u54E5\u3002\u5B83\u5728\u5DF4\u897F\u3001\u82F1\u56FD\u3001\u8377\u5170\u3001\u4E2D\u56FD\u3001\u65B0\u52A0\u5761\u3001\u65E5\u672C\u3001\u6FB3\u5927\u5229\u4E9A\u4E5F\u8BBE\u6709\u5206\u90E8\u3002\u5176\u5458\u5DE5\u8D85\u8FC73000\u4EBA\uFF0C2013\u5E74\u603B\u6536\u5165\u8FBE14.2\u4EBF\u3002\u8BE5\u516C\u53F8\u4E13\u6CE8\u4E8E\u751F\u7269\u4FE1\u606F\u5206\u6790\uFF0C\u63D0\u4F9B\u6709\u5173SNP\u57FA\u56E0\u5206\u578B\u3001\uFF08CNV\uFF09\u3001\u57FA\u56E0\u7EC4\u6D4B\u5E8F\u3001DNA\u7532\u57FA\u5316\u7814\u7A76\u3001\u3001\u76F8\u5173\u7684\u670D\u52A1\u3002\u5982\u4ECA\u7684Illumina\u5DF2\u7ECF\u5360\u6709\u4E86\u57FA\u56E0\u7EC4\u6D4B\u5E8F\u9886\u57DF70%\u7684\u5E02\u573A\u4EFD\u989D\uFF0C\u57282014\u5E74\u8FD8\u88AB\u300AMIT\u6280\u672F\u8BC4\u8BBA\u300B\u9009\u4E3A\u5E74\u5EA650\u5BB6\u6700\u806A\u660E\u516C\u53F8\u7B2C\u4E00\u4F4D\u3002"@zh , "Illumina, Inc. es una compa\u00F1\u00EDa estadounidense fundada en abril de 1998 que desarrolla, fabrica y comercializa sistemas integrados para el an\u00E1lisis de variaci\u00F3n gen\u00E9tica y funci\u00F3n biol\u00F3gica. En 2014 fue nombrada por MIT Technology Review como \"la compa\u00F1\u00EDa m\u00E1s inteligente del mundo\". Mediante el uso de su tecnolog\u00EDa, Illumina proporciona una l\u00EDnea de productos y servicios que sirven a los mercados de secuenciaci\u00F3n, genotipado y expresi\u00F3n g\u00E9nica. Esta tecnolog\u00EDa ha conseguido reducir el coste de secuenciar el genoma humano desde $1.000.000 en 2007 a $4 000 en 2013. Sus clientes incluyen centros de investigaci\u00F3n gen\u00F3mica, compa\u00F1\u00EDas farmac\u00E9uticas, instituciones acad\u00E9micas, organizaciones de investigaci\u00F3n cl\u00EDnica y compa\u00F1\u00EDas biotecnol\u00F3gicas. Sus herramientas proporcionan a los investigadores la capacidad de realizar los tests gen\u00E9ticos necesarios para extraer informaci\u00F3n m\u00E9dica gracias a los avances en gen\u00F3mica y prote\u00F3mica. Su sede se encuentra en San Diego, California. Illumina comenz\u00F3 a ofrecer servicios de genotipado de polimorfismo de nucle\u00F3tido simple (SNP) en 2001 y lanz\u00F3 su primer sistema, el Illumina BeadLab, en 2002. En 2007 la compa\u00F1\u00EDa adquiri\u00F3 Solexa, Inc.(tecnolog\u00EDa de secuenciaci\u00F3n del genoma de la Universidad de Cambridge). En 2007 Illumina vend\u00EDa \u00FAnicamente productos que estaban etiquetados como \"solo uso para investigaci\u00F3n\"; a principios de 2010 Illumina obtuvo la aprobaci\u00F3n de FDA para poder ser usado en test cl\u00EDnicos. Esto fue parte de la estrategia de la compa\u00F1\u00EDa para abrir su propio laboratorio CLIA l y para empezar a ofrecer test gen\u00E9ticos cl\u00EDnicos. En 2015 Illumina origin\u00F3 la compa\u00F1\u00EDa Grail que se centraba en test sangu\u00EDneos para detectar c\u00E1ncer en torrente sangu\u00EDneo. La compa\u00F1\u00EDa est\u00E1 trabajando con pruebas experimentales de test sangu\u00EDneos con alrededor de 120 000 mujeres en los estados de Minnesota y Wisconsin, adem\u00E1s de colaborar con la Mayo Clinic. La compa\u00F1\u00EDa Grail usa la tecnolog\u00EDa de secuenciaci\u00F3n de Illumina para realizar tests y planea lanzar tests en 2019 que costar\u00EDan 500$ por individuo. Actualmente, esta empresa ofrece productos basados en microarrays y todo tipo de servicios relacionados con el an\u00E1lisis gen\u00E9tico (como secuenciaci\u00F3n, an\u00E1lisis de la expresi\u00F3n g\u00E9nica y an\u00E1lisis de prote\u00EDnas)."@es , "Illumina, Inc. est une soci\u00E9t\u00E9 am\u00E9ricaine constitu\u00E9e en avril 1998, qui d\u00E9veloppe, fabrique et commercialise des syst\u00E8mes int\u00E9gr\u00E9s pour l'analyse de la variation g\u00E9n\u00E9tique et la fonction biologique. Gr\u00E2ce \u00E0 ses technologies, la soci\u00E9t\u00E9 fournit une gamme de produits et services qui servent les march\u00E9s du s\u00E9quen\u00E7age, g\u00E9notypage et expression g\u00E9n\u00E9tique. En 2013, cette technologie avait r\u00E9duit le co\u00FBt de s\u00E9quen\u00E7age de l'ADN \u00E0 4 000 dollars, compar\u00E9 \u00E0 1 million de dollars en 2007. Ses clients comprennent des centres de recherche g\u00E9nomique, des soci\u00E9t\u00E9s pharmaceutiques, des \u00E9tablissements universitaires, des organismes de recherche clinique et des soci\u00E9t\u00E9s de biotechnologie. Ses outils offrent aux chercheurs la possibilit\u00E9 d'effectuer des tests g\u00E9n\u00E9tiques n\u00E9cessaires pour extraire l'information m\u00E9dicale des progr\u00E8s de la g\u00E9nomique et de la prot\u00E9omique. Son si\u00E8ge social est situ\u00E9 \u00E0 San Diego aux \u00C9tats-Unis."@fr , "Illumina, Inc. is an American biotechnology company, headquartered in San Diego, California. Incorporated on April 1, 1998, Illumina develops, manufactures, and markets integrated systems for the analysis of genetic variation and biological function. The company provides a line of products and services that serves the sequencing, genotyping and gene expression, and proteomics markets. Illumina's technology had purportedly reduced the cost of sequencing a human genome to US$1,000 by 2014. Its customers include genomic research centers, pharmaceutical companies, academic institutions, clinical research organizations, and biotechnology companies."@en . @prefix prov: . prov:wasDerivedFrom ; dbo:wikiPageLength "34333"^^xsd:nonNegativeInteger ; dbo:assets "1.521E10"^^dbd:usDollar ; dbo:equity "1.074E10"^^dbd:usDollar ; dbo:foundingYear "1998"^^xsd:gYear ; dbo:netIncome "7.6E8"^^dbd:usDollar ; dbo:numberOfEmployees "9100"^^xsd:nonNegativeInteger ; dbo:revenue "4.53E9"^^dbd:usDollar ; dbo:foundedBy dbr:Larry_Bock , dbr:Anthony_Czarnik ; dbo:industry dbr:Biotechnology ; dbo:keyPerson dbr:Francis_deSouza , ; dbo:type dbr:Public_company ; foaf:isPrimaryTopicOf . @prefix ogcgs: . geo:geometry "POINT(-117.17305755615 32.887592315674)"^^ogcgs:wktLiteral .